Lastly, 33.7% of patients who received treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) that suppress cholesterol biosynthesis, have cataracts as a side effect29,30. Here, HMGCR is linked to cataract.